NCT05510427 2023-08-15
Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification
M.D. Anderson Cancer Center
Phase 1 Withdrawn
Clinical Trials
6 trialsNCT04972253 2022-08-10
(BLASST)-3
Dana-Farber Cancer Institute
Phase 1 Withdrawn
NCT01928459 2020-12-09
Phase 1b Trial of BGJ398/BYL719 in Solid Tumors
Novartis
Phase 1 Completed
NCT01697605 2020-12-08
A Phase I Study of Oral BGJ398 in Asian Patients
Novartis
Phase 1 Completed
NCT01004224 2019-10-04
A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies
Novartis
Phase 1 Completed
NCT02312804 2015-02-16
Ph Ib/BGJ398/Cervix and Other Solid Tumors
The University of Texas Health Science Center at San Antonio
Phase 1 Withdrawn